MeiraGTx (Nasdaq: MGTX) has announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis Pigmentosa (XLRP)… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced preliminary efficacy data from a gene therapy for XLRP patients
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a strategic manufacturing services agreement with National Resilience, Inc.… Read More »Opus Genetics Inc., has announced a strategic manufacturing services agreement with National Resilience, Inc., for the development of LCA treatments
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced that the first patient has been dosed in a Phase 1/2 clinical… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced the launch of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the initiation of a Phase 2 clinical trial of ADX-2191… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the launch of a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)
A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the results of a Phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), announces top-line results for the treatment of a novel RNA therapy (“Sepofarsen [QR-110]”) for LCA10
A French bioelectronics company “Pixium Vision SA”, based in Paris, has announced the implantation of an artificial retina in a first patient in the UK. … Read More »Pixium SA has announced the first UK patient enrolled in a “PRIMAvera” study with the implantation of a bionic artificial retina
Neurogene Inc. based in Manhattan, New York City, has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug… Read More »Neurogene Inc. (NYC, USA) has announced to become the first investigative treatment of both neurodegenerative and ocular disease manifestations of Batten Disease.
In follow up the recent French Competent Authority granting of a Cohort Temporary Authorization for Use (“ATU de Cohorte” or ATUc) in July in 2021,… Read More »GenSight Biologics has reported recent research on how gene therapy transfer works migrating vectors from treated to control eyes.
MeiraGTx (Nasdaq: MGTX), has announced two pre-clinical programs addressing Inherited Retinal Diseases (IRDs) caused by mutations in KCNV2 and GUCY2D, for cone-dystrophy, and are presented with… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced two novel IRD research programs on gene therapy
The US FDA has approved a 100 mg/mL ocular implant (Port Delivery System) for the treatment of nAMD, sponsored by Roche (SIX: RO, ROG; OTCQX:… Read More »FDA has approved an implant (Port Delivery System with ranibizumab) to treat neovascular age-related macular degeneration (nAMD)